Allos to Discuss ODAC Panel Recommendation on Monday May 3, 2004

Allos to Discuss ODAC Panel Recommendation on Monday May 3, 2004



WESTMINSTER, Colo., April 30  /PRNewswire-FirstCall/ -- Allos Therapeutics,
Inc.  will hold a conference call Monday afternoon to discuss the outcome of
the Oncologic Drugs Advisory Committee (ODAC) meeting on the company's
investigational radiation sensitizer, RSR13 (efaproxiral). Investors and media
are invited to participate.

   Time:      5:15 PM EDT*
   Date:      Monday, May 3, 2004
   Location:  The Hilton Hotel, Gaithersburg, MD
   Dial-in:   [phone] / [phone] international
   Webcast:   http://www.allos.com/ (homepage and investor relations section)



*If the ODAC meeting continues past 5:15 PM, the start of the conference call
will be delayed until after the meeting's conclusion.

Interested parties unable to participate in the live conference call may access
a recorded rebroadcast by dialing 1-800-428-6051, or [phone] for
international callers; the conference ID number is 353015.  The replay will be
available from 7:00 p.m. ET on Monday, May 3, 2004 until 11:59 PM ET on May 10,
2004.  In addition, the webcast will be archived for on-demand listening for 30
days at http://www.allos.com/.

About Allos Therapeutics, Inc.

Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing
and commercializing innovative drugs for improving cancer treatments.  The
company's lead clinical candidate, RSR13 (efaproxiral), is a synthetic small
molecule that has the potential to sensitize hypoxic (oxygen deprived) tumor
tissues and enhance the efficacy of standard radiation therapy.  In addition,
Allos is developing PDX, an injectable small molecule chemotherapeutic agent
that has a superior potency and toxicity profile relative to methotrexate and
other dihydrofolate reductase, or DHFR, inhibitors.  For more information,
please visit the company's web site at: http://www.allos.com/. 

DATASOURCE: Allos Therapeutics, Inc.



CONTACT:  Monique M. Greer VP, Corporate Communications and Investor

Relations of Allos Therapeutics, Inc., [phone], ; or

Media, Fern Lazar, [phone], or Amy Raskopf, [phone], both of

Lazar Partners Limited, [phone], for Allos Therapeutics, Inc.



Web site:  http://www.allos.com/ 

Copyright